Back to Search Start Over

Fragment Linking Strategies for Structure-Based Drug Design

Authors :
Alexandre Bancet
Claire Raingeval
Thierry Lomberget
Jean-François Guichou
Isabelle Krimm
Marc Le Borgne
Centre de RMN à très hauts champs de Lyon (CRMN)
École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL)
Université de Lyon-Université de Lyon-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)
Molécules bioactives et chimie médicinale (B2MC)
Université Claude Bernard Lyon 1 (UCBL)
Université de Lyon-Université de Lyon
Université de Lyon
Biomolécules Cancer et Chimiorésistances (B2C)
Centre de Biochimie Structurale [Montpellier] (CBS)
Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL)
Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL)
Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
Centre National de la Recherche Scientifique (CNRS)
École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL)
Le Borgne, Marc
Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)
Source :
Journal of Medicinal Chemistry, Journal of Medicinal Chemistry, American Chemical Society, 2020, 63 (20), pp.11420-11435. ⟨10.1021/acs.jmedchem.0c00242⟩, Journal of Medicinal Chemistry, 2020, 63 (20), pp.11420-11435. ⟨10.1021/acs.jmedchem.0c00242⟩
Publication Year :
2020
Publisher :
HAL CCSD, 2020.

Abstract

International audience; Fragment-based drug discovery is a strategy widely used in both academia and pharmaceutical companies to generate small-molecule protein inhibitors and drug candidates. Among the approaches reported in the literature (growing, linking, and merging), the linking approach theoretically offers the opportunity to rapidly gain in binding energy. Nevertheless, this approach is poorly represented when considering the compounds currently in clinical trials. Here, we report an exhaustive view of the cases published so far in the literature, together with the methods used to identify the two initial fragments either simultaneously or successively. We review the different types of linkers published and discuss how these linkers are designed to obtain the lead compound. Mixing merging and linking methods, where the linker is duplicated from a known inhibitor, appears as an interesting strategy. To reach superadditivity, we propose to grow one of the fragments in order to minimize the distance between the two binders and then link the resulting compounds using flexible alkyl-derived linkers.

Details

Language :
English
ISSN :
00222623 and 15204804
Database :
OpenAIRE
Journal :
Journal of Medicinal Chemistry, Journal of Medicinal Chemistry, American Chemical Society, 2020, 63 (20), pp.11420-11435. ⟨10.1021/acs.jmedchem.0c00242⟩, Journal of Medicinal Chemistry, 2020, 63 (20), pp.11420-11435. ⟨10.1021/acs.jmedchem.0c00242⟩
Accession number :
edsair.doi.dedup.....2c05ee129f575cbff72f7c36846be933
Full Text :
https://doi.org/10.1021/acs.jmedchem.0c00242⟩